A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Dupilumab Compared to Placebo in Japanese Patients With Atopic Dermatitis Aged 6 Months to <18 Years Whose Disease is Not Adequately Controlled With Existing Therapies
Latest Information Update: 20 May 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Sanofi
- 12 Dec 2023 Status changed from active, no longer recruiting to completed.
- 08 Aug 2023 Planned End Date changed from 1 Sep 2023 to 31 Oct 2023.
- 06 Sep 2021 Status changed from recruiting to active, no longer recruiting.